Antibody-drug conjugate
From Self-sufficiency
Antibody-drug conjugates (ADCs) are a new type of targeted therapy eg for cancer.[1] [2] [3] [4] They consist of an antibody (or antibody fragment such as a single-chain variable fragment (scFv)) linked to a payload drug (often cytotoxic). Hence they are a type of immunoconjugate.
The antibody causes the ADC to bind to the target cancer cells. Often the ADC is then internalised by the cell and the drug is released to do its damage.[5]
Approved:
- gemtuzumab ozogamicin (Mylotarg) Approved for acute myelogenous leukemia in 2001 but since withdrawn.
Examples in clinical trials :[1][6]
Phase III : none as of early 2008
Phase II:
- Glembatumumab vedotin for melanoma and metastatic breast cancer.
- Trastuzumab-DM1 (T-DM1)[7][8] for breast cancer.
- IMGN242[9] for CanAg expressing gastric cancer.
- lorvotuzumab mertansine (IMGN901) for CD56 cancers.[10]
Phase I:
Preclinical:
- Anti-CD22-MCC-DM1 for leukemia[13]
- and others.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." /> |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ 1.0 1.1 http://pharmtech.findpharma.com/pharmtech/Ingredients+Insider/Antibody-Drug-Conjugates-A-Marriage-of-Biologics-a/ArticleStandard/Article/detail/522139
- ↑ http://pubs.acs.org/doi/abs/10.1021/bc9002019
- ↑ http://cancerres.aacrjournals.org/content/66/6/3214.abstract
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/17553616
- ↑ http://cancerres.aacrjournals.org/content/52/1/127.full.pdf+html Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs. Chari et al. 1992
- ↑ http://pharmtech.findpharma.com/pharmtech/data/articlestandard//pharmtech/232008/522139/i3.jpg ADCs in early 2008
- ↑ http://www.cancer.gov/drugdictionary/?CdrID=564399
- ↑ http://www.news-medical.net/news/20100827/FDA-denies-accelerated-approval-of-Genentechs-trastuzumab-DM1-%28T-DM1%29-BLA-for-metastatic-breast-cancer.aspx
- ↑ http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33509
- ↑ http://www.news-medical.net/news/20091206/ImmunoGen-reports-encouraging-clinical-data-of-IMGN901.aspx
- ↑ http://www.ncbi.nlm.nih.gov/pubmed/12525512 Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. 2003 Abstract
- ↑ http://jco.ascopubs.org/content/21/2/211.full Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. Tolcher et al. 2003. Full text
- ↑ http://www.nature.com/leu/journal/vaop/ncurrent/abs/leu2010141a.html
